Publish in this journal
Journal Information
Vol. 73. Issue 2.
Pages 131-138 (February 2020)
Not available
Vol. 73. Issue 2.
Pages 131-138 (February 2020)
Original article
Full text access
Determinants of long-term outcome of repaired pulmonary valve stenosis
Determinantes del resultado a largo plazo de la estenosis de válvula pulmonar reparada
Laura Galian-Gaya,
Corresponding author

Corresponding author: Cardiology Department, Vall d’Hebron Hospital, Passeig de la Vall d’Hebron 119-129, 08035 Barcelona, Spain.
, Blanca Gordona, Josep Ramón Marsalb, Agnès Rafecasa, Antonia Pijuan Domènechc, Miguel Angel Castroc, Maria T. Subirana Domènechc, Carlos Suredad, Berta Mirandac, Gerard Martía, David García-Doradoa, Laura Dos Subiràc
a Servei de Cardiología, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Barcelona, España
b Unitat d’Epidemiologia, Servei de Cardiología, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, CIBERESP, Barcelona, España
c Servei de Cardiología, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Unitat Integrada de Cardiopaties Congènites de l’Adolescent i de l’Adult Vall d’Hebron-Sant Pau, Barcelona, España
d Servei de Cirurgia Cardiaca, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Related content
Rev Esp Cardiol. 2020;73:107-910.1016/j.rec.2019.07.012
Heleen B. van der Zwaan, Bart W. Driesen, Folkert J. Meijboom
This item has received
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (3)
Table 1. Baseline (preoperative) data
Table 2. Follow-up data
Table 3. Bivariate associations between baseline characteristics and long-term cardiovascular complications and need for reintervention
Show moreShow less
Introduction and objectives

Although pulmonary valve stenosis (PVS) is considered a low risk congenital heart disease, there have been reports of complications and the need for reintervention throughout follow-up. The aims of this study were to evaluate the long-term outcome of repaired PVS and to identify predictors of cardiovascular complications and reintervention.


We studied 158 adult patients with repaired PVS (repair procedures performed from 1957 to 2010) receiving active follow-up in a tertiary referral center.


A total of 95 patients (60%) received surgical treatment, and 63 patients (40%) received percutaneous pulmonary balloon valvuloplasty. At the end of follow-up (27 years, IQR, 20-33 years), most patients (n=134, 84.8%) were in New York Heart Association functional class I, but 61 patients (38.6%) required a reintervention, mainly pulmonary valve replacement (17.7%, n=28), and 19 patients (12%) had at least one cardiovascular complication: 13 (8.2%) supraventricular arrhythmias, 6 (3.8%) heart failure, 5 (3.2%) stroke, 1 (0.6%) death, 1 (0.6%) thromboembolism, and 1 (0.6%) ventricular arrhythmia. Multivariate analysis showed that age at PVS repair (HR, 1.08; 95%CI, 1.04-1.12; P <.001) and the presence of cyanosis before PVS repair (HR, 5.23; 95%CI, 1.99-13.78; P=.001) were independent predictors for cardiovascular complications.


Good long-term outcome can be expected after PVS repair, but complications and the need for reintervention may appear. Older age and the presence of cyanosis at PVS repair emerged as predictors of cardiovascular complications and identified a population that may merit stricter control.

Pulmonic valve stenosis
Congenital heart disease surgery
Transcatheter valve interventions
Cardiac complications
Introducción y objetivos

Aunque la estenosis de la válvula pulmonar (EVP) se considera una cardiopatía congénita de bajo riesgo, se ha descrito la aparición de complicaciones y necesidad de reintervenir durante el seguimiento. Los objetivos del estudio fueron evaluar los resultados a largo plazo de la EVP reparada e identificar predictores de complicaciones cardiovasculares y reintervención.


Se estudió a 158 pacientes adultos con EVP reparada (reparaciones practicadas de 1957 a 2010) con seguimiento activo en un centro terciario de referencia.


Se sometió a cirugía a 95 pacientes (60%) y a valvuloplastia percutánea con balón a 63 (40%). Tras una mediana de seguimiento de 27 [20-33] años, la mayoría de los pacientes (n=134 [84,8%]) estaban en clase funcional I de la New York Heart Association, pero 61 (38.6%) requirieron reintervención, principalmente reemplazo de la valvular pulmonar (n=28 [17,7%]), y 19 (12%) presentaron al menos una complicación cardiovascular: 13 (8,2%), arritmias supraventriculares; 6 (3,8%), insuficiencia cardiaca; 5 (3,2%), accidente cerebrovascular; 1 (0,6%), muerte; 1 (0,6%) tromboembolia, y 1 (0,6%), arritmia ventricular. El análisis multivariante mostró que la edad en el momento de la reparación de la EVP (HR=1,08; IC95%, 1,04-1,12; p <0,001) y la presencia de cianosis antes de la reparación (HR=5,23; IC95%, 1,99-13,78; p=0,001) fueron predictores independientes de complicaciones cardiovasculares.


Se puede esperar un buen resultado a largo plazo tras de la reparación de la EVP, pero pueden aparecer complicaciones y necesidad de reintervenir. Una edad más avanzada y la presencia de cianosis en el momento de la reparación de la EVP son predictores de complicaciones cardiovasculares e identifican a una población que requiere un control más estricto.

Palabras clave:
Estenosis de la válvula pulmonar
Cirugía de cardiopatía congénita
Intervenciones percutáneas valvulares
Complicaciones cardiacas
Full Text

Pulmonary valve stenosis (PVS) is a common cause of right ventricular outflow tract obstruction that affects 7% to 12% of patients with congenital heart disease.1 When technically feasible, percutaneous balloon valvuloplasty is currently the strategy of choice but there is a huge population of patients in follow-up that underwent surgical repair in earlier eras. Overall, PVS is considered a low risk congenital heart disease with near normal life expectancy,2–4 but a number of cardiac events (predominantly supraventricular arrhythmias) may appear throughout follow-up.5 There is, however, a paucity of published data addressing this issue. In addition, pulmonary regurgitation is a common finding in the long-term and a need for reintervention may ensue. The aim of this study was to evaluate the long-term outcome of repaired PVS and to identify predictors of cardiovascular complications and reintervention.


Two hundred eleven patients (≥ 16 years) with repaired PVS were identified using a prospectively maintained database of the congenital heart disease unit of a single tertiary referral center. Of these, 158 patients were receiving active follow-up at the same center or at peripheral congenital cardiac units (at least 1 visit in the preceding 5 years) and constituted the study population. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the human research committee of our institution. PVS repair procedures were performed between 1957 and 2010, predominantly at our institution, and included surgical treatment in 95 patients (60%, from 1957) and percutaneous pulmonary balloon valvuloplasty in 63 patients (40%, from 1985). Patients with associated congenital heart defects other than atrial septal defect (ASD), patent foramen ovale (PFO) or patent ductus arteriosus were excluded. Demographic data, preoperative information, surgical details and last follow-up data (including clinical status, electrocardiogram, echocardiography, and cardiac magnetic resonance when available) were retrospectively obtained from the patients records. Right atrial enlargement on the ECG was considered when the P wave height measured> 2.5mm (2.5mV) in inferior leads and> 1.5mm in V1 or, in the absence of ECG tracings, when recorded as such in the clinical records. Cyanosis was collected as a dichotomous variable and considered positive when O2 saturation was <90% or, in the absence of O2 saturation data, when clinical records stated so based on physical examination. Events of interest were reintervention (considered as any cardiac surgery or percutaneous treatment of a residual defect performed after the initial repair) and cardiovascular complications defined as a composite endpoint of cardiovascular death, heart failure (clinical signs of right heart congestion), arrhythmia (sustained supraventricular tachycardia and sustained/nonsustained ventricular tachycardia), stroke, and embolism. Pulmonary artery (PA) dilation was considered when the PA trunk measured ≥ 40mm by an imaging technique (echocardiography, computed tomography, or cardiac magnetic resonance). Hemodynamic data were completed using catheterization records. Echocardiographic data were revised from patients’ records. Studies were performed and reported according to the current European Echocardiography Guidelines at the moment of the diagnostic test. Pulmonary regurgitation and tricuspid regurgitation were objectively evaluated according to the parameters described in the guidelines.

Continuous variables are described as mean±standard deviation and as median and interquartile range (IQR) when a normal distribution could not be demonstrated. Categorical variables are described as percentages. Comparisons between variables were performed by the Student t test, chi-square test or nonparametrical Mann-Whitney U-test and Fisher's exact test as appropriate. Cox proportional hazard models were performed to quantify the bivariate association between baseline variables and outcomes of interest (cardiovascular complications and need for reintervention). All the variables with statistical significance in the bivariate analysis <0.2 were selected for multivariable modelling, which included forward and backward stepwise methods with a threshold for exit set at P higher than .10 and for entering at P lower than .10. Proportional hazard assumption was graphically checked. Interaction between variables was tested.

Survival free of cardiovascular complications and need for reintervention was estimated using Kaplan-Meyer curves for the surgical and percutaneous valvuloplasty cohorts and was compared by log-rank test. Patients were censored when the first event occurred.

RESULTSBaseline data: general overview

Surgical treatment was more frequent in our cohort as a whole, predominantly in the early years. The most frequently performed surgical procedure was valvulotomy (n=92; 92.8%) with or without infundibulectomy in 41 (43.1%) patients. Three patients (3.1%) underwent valvulectomy. Additional ASD/PFO closure was performed in 20 patients (21%), transannular patch in 6 (6.3%) and ventriculotomy was required in 12 (12.6%).

Table 1 contains all the demographic and preoperative data of the entire cohort and in 2 subgroups according to the type of procedure performed (surgery or valvuloplasty). The median age at repair was 3 years (IQR, 1-7 years) in the group as a whole. About one third of the cohort (n=55, 34.8%) had associated ASD/PFO and approximately a third of the patients (n=46, 31.1%) had symptoms before PVS repair (either cyanosis, congestive heart failure, arrhythmia, or exercise intolerance).

Table 1.

Baseline (preoperative) data

Variables  All patientsN=158  Surgeryn=95 (60%)  Percutaneous valvuloplastyn=63 (40%)  P 
Female sex  75 (47.5)  43 (45.3)  32 (50.8)  .535 
Age at repair, y  3 [1-7]  2 [0-7]  4 [1-11]  .028 
Associated infundibular stenosis  53 (33.5)  40 (42.1)  13 (20.6)  .013 
Associated congenital defects  67 (42.4)  50 (52.6)  17 (27)  .010 
Associated ASD/PFO  55 (34.8)  40 (42.1)  15 (23.8)   
Associated PDA  8 (5.1)  6 (6.3)  2 (3.2)   
Associated ASD/PFO and PDA  4 (2.5)  4 (4.2)  0 (0)   
Symptoms  46 (29.1)  36 (37.9)  10 (15.9)  .002 
Exercise intolerance  19 (12.1)  12 (12.6)  7 (11.1)   
Congestive heart failure  1 (0.6)  1 (1.1)  0 (0)   
Cyanosis  29 (18.3)  27 (28.4)  2 (3.2)   
Need for medical treatment  8 (5.1)  8 (8.4)  0 (0)  .015 
Sinus rhythm  138 (87.3)  79 (83.2)  59 (93.6)  .389 
Cardiomegaly  43 (27.2)  34 (35.8)  9 (14.3)  .001 
Hemodynamic data (n=116)
Peak gradient (PA-RV)  74.81±31.8  80.2±36.5  69.9±26.3  .217 
Systolic RV pressure, mmHg  95.6±34.8  104.2±39  85.8±26.1  .006 
Right atrial pressure, mmHg  5.09±4.1  4.9±5.25±2.6  .112 
Cardiac index, L/min/m2  5.3±3.5  5.9±4.5  4.7±1.8  .130 

ASD, atrial septal defect; PA-RV, pulmonary artery-right ventricle; PDA, patent ductus arteriosus; PFO, patent foramen ovale; RV, right ventricular.

Data are presented as mean±standard deviation, No. (%), or median [interquartile range].

Baseline data: comparison between surgical and percutaneous cohorts

Statistically significant differences were observed between patients undergoing surgery compared with those undergoing percutaneous valvuloplasty, in terms of age at time of PVS repair (4.8±7.0 vs 8.3±12.4; P=.028), systolic pressure of right ventricle (RV) (104.2±39 vs 85.8±26mmHg; P=.006), presence of symptoms (41% vs 16.7%; P=.002) and, therefore, need for medical treatment (9.3% vs 0.0%; P=.015). However, the severity of stenosis (peak RV - PA gradient): 80.2±36.5 vs 69.9±26.3mmHg; P=.217) was not significantly different. As expected, patients undergoing surgical repair more frequently had associated infundibular stenosis (42.1% vs 20.6%; P=.013) or ASD/PFO or patent ductus arteriosus requiring closure (52.6% vs 27%; P=.010).

Last follow-up data: general overview

After a median follow-up of 27 years (QR, 20-33 years, surgical cohort 32 years [IQR, 28-36 years], percutaneous valvuloplasty 20 years [IQR, 17-23 years]; P <.001), most patients were in New York Heart Association functional class I and only 31 patients (19.6%) needed medical treatment (either beta-blockers, digoxin, diuretics, oral anticoagulation, or antiarrhythmic drugs). Most of them were in sinus rhythm (n=150; 94.9%) and right bundle branch block was present in 52 (33.1%) with a global mean QRS duration of 107.7±23.5ms (135±15.6ms for those with right bundle branch block). Echocardiography evaluation in the last follow-up visit showed residual pulmonary stenosis with peak gradient ≥ 36mmHg (39±3mmHg) in only 3% (n=5) of patients. Moderate to severe pulmonary regurgitation was present in more than a half of the cohort (n=89; 56.7%) at the end of follow-up and moderate to severe right ventricular dilation was seen in 39 (24.7%). For patients requiring reintervention with pulmonary valve replacement, the peak gradient through the prosthetic valve was 22.8±8.3mmHg with only mild-or-mild to moderate pulmonary regurgitation.

Forty-six pregnancies were registered among 31 women in our cohort, and a single patient had complications before delivery. A 30-year-old patient with history of PVS surgically repaired at 3 days of life, with subsequent development of severe pulmonary regurgitation, presented at 36 weeks of gestation with cyanosis and peripheral oedema. Complementary tests showed restrictive RV pattern and the presence of an ostium secundum ASD near the entrance of the inferior vena cava. The patient was prescribed bed rest and some fluid restriction and delivered at 38 weeks with no further complications.

Heart disease in the offspring was detected in only 1 case (mild PVS).

Last follow-up data: comparison between surgical and percutaneous cohorts

Statistically significant differences were found between the surgical group and the percutaneous valvuloplasty group in terms of the presence of right bundle branch block (43.6% vs 17.5%; P=.001) and, therefore, QRS duration (115±25ms vs 96±15ms; P <.001). Systolic function of the RV evaluated by tricuspid annular plane systolic excursion (17.9±4mm vs 21.8±3.6mm; P <.001) was statistically significantly different between both groups. The remaining data related to the last follow-up visit is summarized in Table 2.

Table 2.

Follow-up data

  All patients N=158  Surgery n=95 (60%)  Percutaneous valvuloplasty n=63 (40%)  P 
Clinical data. Electrocardiogram and echocardiographic characteristics at the last follow-up visit
Age at last follow-up, y  34 [26-39]  37 [32-42]  27 [21-31]  <.001 
NYHA functional class        <.001 
134 (84.8)  72 (75.8)  62 (98.4)   
II  23 (14.6)  22 (23.2)  1 (1.6)   
III  0 (0)  0 (0)  0 (0)   
IV  1 (0.5)  1 (1.1)  0 (0)   
Need for medical treatment  31 (19.6)  28 (29.5)  3 (4.8)  <.001 
Sinus rhythm  150 (94.9)  88 (92.6)  62 (98.4)  .105 
Right bundle branch block  52 (33.1)  41 (43.6)  11 (17.5)  .001 
Signs of right atrial enlargement  35 (23.2)  25 (27.8)  10 (16.4)  .104 
Moderate-severe PR  89 (56.7)  63 (67)  26 (41)  .001 
Moderate-severe TR  25 (15.8)  23 (24.2)  2 (3.2)  <.001 
TAPSE, mm  19.4±4.3  17.9±21.8±3.6  <.001 
Presence of ASD/PFO  12 (7.6)  7 (7.4)  5 (7.9)  .895 
Cardiovascular complications during follow-up
Any cardiovascular complication  19 (12)  18 (18.9)  1 (1.6)  .001 
Supraventricular tachycardia  13 (8.2)  13 (13.7)  0 (0)  .002 
Heart Failure  6 (3.8)  6 (6.3)  0 (0)  .04 
Stroke  5 (3.2)  4 (4.2)  1 (1.6)  .36 
Cardiovascular death  1 (0.6)  1 (1.1)  0 (0)  .42 
Thromboembolism  1 (0.6)  1(1.1)  0 (0)  .41 
Nonsustained VT  1 (0.6)  1 (1.1)  0 (0)  .41 
Type of reintervention during follow-up
Any reintervention  61 (38.6)  42 (44.2)  19 (30.2)  .076 
Pulmonary valve replacement  28 (18.2)  26 (28)  2 (3.3)  <.001 
RV outflow tract enlargement  13 (8.4)  7 (7.5)  6 (9.8)  .61 
ASD/PFO closure  13 (8.4)  9 (9.7)  4 (6.6)  .5 
Percutaneous balloon valvuloplasty  11 (7.1)  4 (4.3)  7 (11.5)  .09 
Valvulotomy/commissurotomy  10 (6.5)  1 (1.1)  9 (14.8)  .001 
Pulmonary artery plasty  3 (1.9)  2 (2.2)  1 (1.6)  .82 

ASD, atrial septal defect; NYHA, New York Heart Association; PFO, patent foramen ovale; PR, pulmonary regurgitation; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; VT, ventricular tachycardia.

Data are presented as median [interquartile range] or No. (%).

Long-term cardiovascular complications

Median age at last follow-up was 34 years (IQR, 26-39 years). PA dilation ≥ 40mm was present in 14 patients (8.8%) with a mean diameter of 45.2±6.8mm (maximum diameter 60mm). A patient with a PA of 60mm and severe pulmonary regurgitation developed angina due to left main coronary compression. After PVR and PA resection (interposition of a valved conduit), the compression and its symptoms resolved.

No episodes of endocarditis were documented.

At the end of follow-up, 19 patients (12%) had a cardiovascular complication (as previously defined). Survival free of cardiovascular complications at 10 and 20 years was 99% and 96%, respectively, in the surgical cohort and 100% and 93%, respectively, in the percutaneous valvuloplasty cohort (P=.6) (Figure 1).

Figure 1.

Survival curves according to cardiovascular complications.


The individual components of the composite endpoint are outlined in Table 2. There was only 1 death in our series. A 78-old-year man had PVS repair consisting of valvulotomy and infundibular resection at the age of 35 years. At 65 years, permanent atrial fibrillation was diagnosed and 1 year later the patient showed progressively worsening New York Heart Association functional class and signs of peripheral congestion. A moderate-to-severe pulmonary regurgitation was documented with moderate RV dilation and mild depressed systolic RV function. The subsequent clinical course was fatal due to refractory heart failure and death.

The only variables associated with cardiovascular complication in the bivariate analyses (Table 3) were age (HR, 1.07; 95%CI, 1.03-1.12; P <.001) and cyanosis at PVS repair (HR, 4.32; 95%CI, 1.66-11.25; P=.003). Both variables remained predictors for cardiovascular complications on multivariable analysis (age at PVS repair: HR, 1.08; 95%CI, 1.04-1.12; P <.001, cyanosis: HR, 5.23; 95%CI, 1.99-13.78; P=.001). Moreover, a statistically significant interaction between the 2 variables emerged (P <.001), which can be seen in Figure 2. The relationship between age at intervention and cardiovascular events depended on the presence of cyanosis. In patients with cyanosis, there was a higher risk of cardiovascular complications regardless of age at repair (although there was a higher risk in those repaired at an older age). In contrast, in patients without cyanosis, age at repair was associated with a lower risk of cardiovascular events in those undergoing surgery at a young age, whereas the risk progressively increased in those patients undergoing surgery at older ages.

Table 3.

Bivariate associations between baseline characteristics and long-term cardiovascular complications and need for reintervention

  HR (95%CI)  P 
Male sex  1.46 (0.57-3.74)  .43 
Age at repair  1.07 (1.03-1.12)  .001 
Associated infundibular stenosis  0.6 (0.22-1.6)  .31 
Associated ASD/PFO  1.58 (0.61-4.12)  .35 
Cyanosis  4.32 (1.66-11.25)  .003 
Need for medical treatment  0.47 (0.06-3.63)  .47 
Sinus rhythm  0.9 (0.28-2.89)  .86 
Cardiomegaly  2.22 (0.64-7.65)  .21 
Hemodynamic data (n=116)     
Peak gradient (PA-RV), mmHg  1.01 (0.99-1.03)  .24 
Systolic RV pressure, mmHg  1.01 (0.99-1.02)  .35 
Right atrial pressure, mmHg  0.95 (0.80-1.14)  .60 
Percutaneous valvuloplasty  0.53 (0.06-4.56)  .56 
Transannular patch  -*  -* 
Female sex  1.52 (0.91-2.56)  .11 
Age at repair  0.94 (0.89-0.99)  .035 
Associated infundibular stenosis  1 (0.59-1.69)  .99 
Associated ASD/PFO  1.41 (0.83-2.24)  .21 
Cyanosis  2.57 (1.47-4.5)  .001 
Need for medical treatment  0.42 (0.15-1.17)  .1 
Sinus rhythm  1.18 (0.59-2.35)  .64 
Cardiomegaly  1.8 (0.98-3.31)  .06 
Hemodynamic data (n=116)
Peak gradient (PA-RV), mmHg  1 (0.99-1.01)  .66 
Systolic RV pressure, mmHg  1 (0.99-1.01)  .77 
Right atrial pressure, mmHg  0.9 (0.81-1.01)  .07 
Percutaneous valvuloplasty  1.99 (1.03-3.84)  .041 
Transannular patch  0.63 (0.15-2.59)  .52 

95%CI, 95% confidence interval; ASD, atrial septal defect; HR, hazard ratio; PA-RV, pulmonary artery-right ventricle; PFO, patent foramen ovale; RV, right ventricular.


Coefficient estimation of the model is not possible because there were no complications in patients with transannular patch.

Figure 2.

Interaction between cyanosis and age at repair in the development of cardiovascular complications.

Long-term need for reintervention

After PVS repair, a total of 61 patients (38.6%) required additional procedures, 10 of them (16.4% of the reintervention group) required 2 reinterventions and 4 of them (6.5% of the reintervention group) ≥ 3 reinterventions. In addition, 5 of these patients required either pacemaker/defibrillator implantation or ablation procedures at the time of the reintervention or during follow-up. Survival free of need for reintervention at 10, 15 and 20 years was 88%, 87%, and 85%, respectively, in the surgical cohort and 74%, 72% and 70%, respectively, in the percutaneous valvuloplasty cohort (P=.03) (Figure 3).

Figure 3.

Kaplan-Meier survival curves according to reintervention.


The most frequent procedures were pulmonary valve replacement, ASD/PFO closure, and right outflow tract enlargement techniques. Information related to reintervention is described in Table 2. In the bivariate analyses (Table 3) need for reintervention was associated with younger age at PVS repair (HR, 0.94; 95%CI, 0.89-0.99; P=.035), the presence of cyanosis prior to repair (HR, 2.57; 95%CI,1.47-4.5; P=.001), and the use of percutaneous valvuloplasty (HR, 1.99; 95%CI, 1.03-3.84; P <.041). In the multivariate analysis, the presence of cyanosis prior to repair (HR, 3.17; 95%CI,1.68-5.97; P <.001) and the use of percutaneous valvuloplasty (HR, 3.48; 95%CI,1.67-7.25; P=.001) remained predictors for reintervention. The most frequent reintervention in patients undergoing initial percutaneous valvuloplasty for PVS repair was surgical comisurotomy/valvotomy (Table 2). As seen in the Kaplan-Meyer curves, the need for reintervention in the percutaneous valvuloplasty group occured soon after the initial procedure and in the early era of the procedure (57% of the 14 patients who underwent percutaneous valvuloplasties between 1985-1988 required reintervention, whereas only 21% of the remaining 48 patients did so, P=.02).


This series comprises a tertiary referral center cohort of patients with isolated PVS repaired either with surgery or percutaneous valvuloplasty. After a median follow-up of 27 years, although the average survival rate and functional class were good, 38.6% of patients required reintervention and 12% had cardiovascular complications.

Several studies have reported excellent outcomes in patients with repaired PVS,2–4,6 with good functional class at the end of follow-up, as in our study, and survival similar or only slightly shorter than those in the general population.4,7 Nonetheless, complications and, mainly, the need for reintervention have been described during follow-up.2–6

The reported need for reintervention varies widely among the various series.3,8 Kopecky et al.,4 in their surgical series published in 1988 (191 patients, 24.4 years of follow-up), observed a need for reintervention of only 2.6%.In 2005, the same group reported a reintervention rate of 53%, mostly related to pulmonary regurgitation, in a selected cohort of 53 patients drawn from the adult congenital cardiac unit database (follow-up 33 years).3 Other contemporary series reporting results after percutaneous balloon valvuloplasty also show a variable rate of reintervention (2%-30%), mainly related to residual PVS.9,10

In a cohort of 158 patients (60% surgical and 40% percutaneous) and after a median follow-up of 27 years, we report a reintervention rate of 38.6%. This variability in the reported reintervention rate may be explained by several factors: the difference in length of follow-up between series, the different techniques used for PVS relief, and the evolving criteria for reintervention of the residual lesions, particularly pulmonary regurgitation. Moreover, some series include as reinterventions the implantation of pacemakers/defibrillators or ablation techniques, whereas others do not. As for predictors of reintervention, the literature points to technical issues at the time of initial PVS repair: the use of transannular patch3 and closed valvotomy5 in surgical patients and the balloon to annulus ratio in percutaneous patients.10 In our series, despite the surgical cohort accounting for a larger number of reinterventions, as shown in Table 1, percutaneous valvuloplasty emerged as a risk factor for reintervention after adjustment for time of follow-up. In view of the association of the need for reintervention with the early era of the procedure, however, this may be interpreted as a “failed strategy” of percutaneous valvuloplasty during the learning curve of the technique itself and candidate selection. More intriguing is the relationship of cyanosis prior to PVS repair with the need for reintervention.

While several articles in the literature elaborate on the need for reintervention, there is a paucity of data on predictors of cardiac complications after PVS relief. In a comprehensive report published in 1988, Kopecky et al.4 focused on the long-term complications of their surgical series (median follow-up of 24.3 years) and reported cardiovascular events in 20 patients (10.4%): cardiovascular death in 11, congestive heart failure in 2, reinterventions for residual pulmonary stenosis in 5, and pacemaker implantations in 2. Independent predictors for such events were advanced age at time of repair and higher preoperative and postoperative right ventricular pressure. Although there is some information about long-term complications in the recent literature, there is no other study focusing on predictive factors. In our contemporary cohort of 158 patients with active follow-up (median 27 years) in a tertiary referral congenital cardiac unit, 19 patients (12%) had cardiac complications, namely cardiovascular death, heart failure, arrhythmia, stroke, and embolism. The multivariate analysis identified cyanosis and older age at repair as the factors likely associated with late cardiovascular complications.

The relationship between older age at repair and cardiovascular complications may reflect the deleterious effect of long-term right ventricular pressure overload and the subsequent ventricular hypertrophy and myocardial fibrosis. Right ventricular fibrosis is well recognized to occur as a result of severe pulmonary stenosis and it increases progressively with age to be universally present by the age of 30 or older.11 Recent studies examining the presence of restrictive RV physiology by cardiac magnetic resonance have found a strong association with fibrosis evaluated by late gadolinium enhancement.12 In adults with tetralogy of Fallot, extensive presence of late gadolinium enhancement in the RV was related to adverse clinical markers, including decreased exercise tolerance and clinical arrhythmia.13–15 Currently, arrhythmia is the major driver of our composite endpoint of cardiovascular complications.

Ross-Hesselink et al.3 reported recurrent supraventricular tachycardia in only 3 patients (3.3%). In an update of that cohort The same group,10, described only an additional patient with atrial arrhythmias. The authors do not describe complex ventricular arrhythmias in their surgical cohort but report nonsustained ventricular tachycardia in 2% of Holter monitoring and 1 case of sudden cardiac death 25 years after surgical repair. Sudden cardiac death has been seldom reported in other series.6,8

The other predictor of cardiovascular complications in our study was the presence of cyanosis before PVS relief, as proposed by the group of Helen Taussig back in 1963.16 Moreover, in our study, a statistically significant interaction was detected between both predictors so that the relationship between age at repair and the risk of cardiovascular events was somehow mediated by the presence of cyanosis, which conferred a poor prognosis at any age.

Cyanosis is attributed to a right-to-left shunt through a PFO. Although it may reflect more severe pulmonary stenosis, when assessing the parameters of severity of the lesion (the RV systolic pressure and the pulmonary valve gradient), no association was found with the occurrence of cardiovascular complications. It can be speculated that cyanosis reflects a worse myocardial adaptation to the maintained pressure overload situation in the neonatal period and during the early stages of life. The intrinsic mechanisms of this unfavorable myocardial adaptation (possibly also related to RV diastolic dysfunction) may persist after PVS relief, leading to a higher rate of cardiac complications and need for reintervention.


The main limitation of this study is its retrospective nature. Of the 211 patients with repaired PVS identified in our database, only 158 were receiving active follow-up and constituted the study population. The search for information was mainly done through the medical records of our center or referral cardiologists and, in some cases, based on primary physician electronic records. Although a 25% loss to follow-up should be considered by all means excessive, recent studies report rates of up to 42% of gaps in care among patients with adult congenital heart disease, 8% of which lasted for more than 10 years17. The main reason for discontinuation of care in these studies, regardless the cardiac complexity, was the fact that patients felt well and did not feel that further follow-up was necessary.

The length of follow-up of the surgical and the percutaneous valvuloplasty group were significantly different. Although percutaneous valvuloplasty emerged as a predictor of need for reintervention, this finding was based on the statistical assumption that the risk for reintervention of both populations remains constant through time and, as shown in the Kaplan-Meir curves, this might not be the case.


Patients with repaired PVS had an excellent postoperative outcome. Nonetheless, complications and the need for reintervention may appear in the long-term. PVS repair at an older age and the presence of cyanosis before PVS relief, both factors probably reflecting a worse right ventricular myocardium profile after repair, emerged as predictors of unfavorable outcome and identified a population that may merit closer follow-up.


This study was funded by CIBERCV and co-financed by the European Regional Development Fund (ERDF-FEDER).


None declared.


  • -

    Repaired PVS is considered a low-risk congenital cardiac condition with near-normal life expectancy. However, there have been reports of long-term complications after PVS repair.


  • -

    Long-term outcome was reviewed in a contemporary population of repaired PVS patients. Reintervention was required in 38% of the patients and cardiovascular complications occurred in 12%. The main finding of our study was that older age at repair and, more importantly, cyanosis prior to repair were independent predictors of the composite endpoint of cardiovascular complications (cardiovascular death, heart failure, arrhythmia, stroke, and embolism).

Nykanen DG. Pulmonary Atresia and Intact Ventricular Septum. In Allen HD, Shaddy RE, Penny DJ, Feltes TF, Cetta F, eds. Moss and Adams’ Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adults. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 913-920.
C.J. Hayes, W.M. Gersony, D.J. Driscoll, et al.
Second natural history study of congenital heart defects. Results of treatment of patients with pulmonary valvar stenosis.
Circulation., 87 (1993), pp. I28-I37
J.W. Roos-Hesselink, F.J. Meijboom, S.E. Spitaels, et al.
Long-term outcome after surgery for pulmonary stenosis (a longitudinal study of 22-33 years).
Eur Heart J., 27 (2006), pp. 482-488
S.L. Kopecky, B.J. Gersh, M.D. McGoon, et al.
Long-term outcome of patients undergoing surgical repair of isolated pulmonary valve stenosis. Follow-up at 20-30 years.
Circulation., 78 (1988), pp. 1150-1156
M.G. Earing, H.M. Connolly, J.A. Dearani, N.M. Ammash, M. Grogan, C.A. Warnes.
Long-term follow-up of patients after surgical treatment for isolated pulmonary valve stenosis.
Mayo Clin Proc., 80 (2005), pp. 871-876
A. Voet, F. Rega, A.V. de Bruaene, et al.
Long-term outcome after treatment of isolated pulmonary valve stenosis.
Int J Cardiol., 156 (2012), pp. 11-15
C.D. Morris, V.D. Menashe.
25-year mortality after surgical repair of congenital heart defect in childhood. A population-based cohort study.
JAMA., 266 (1991), pp. 3447-3452
E.A. Nielsen, V.E. Hjortdal.
Surgically treated pulmonary stenosis: over 50 years of follow-up.
Cardiol Young., 26 (2016), pp. 860-866
J.A. Cuypers, M. Witsenburg, D. van der Linde, J.W. Roos-Hesselink.
Pulmonary stenosis: update on diagnosis and therapeutic options.
J.A. Cuypers, M.E. Menting, P. Opic, et al.
The unnatural history of pulmonary stenosis up to 40 years after surgical repair.
M. Jones, V.J. Ferrans.
Myocardial degeneration in congenital heart disease. Comparison of morphologic findings in young and old patients with congenital heart disease associated with muscular obstruction to right ventricular outflow.
Am J Cardiol., 39 (1977), pp. 1051-1063
P. Munkhammar, M. Carlsson, H. Arheden, E. Pesonen.
Restrictive right ventricular physiology after tetralogy of Fallot repair is associated with fibrosis of the right ventricular outflow tract visualized on cardiac magnetic resonance imaging.
Eur Heart J Cardiovasc Imaging., 14 (2013), pp. 978-985
S.V. Babu-Narayan, P.J. Kilner, W. Li, et al.
Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome.
Circulation., 113 (2006), pp. 405-413
W.A. Helbing, R.A. Niezen, S. Le Cessie, R.J. van der Geest, J. Ottenkamp, A. de Roos.
Right ventricular diastolic function in children with pulmonary regurgitation after repair of tetralogy of Fallot: volumetric evaluation by magnetic resonance velocity mapping.
J Am Coll Cardiol., 28 (1996), pp. 1827-1835
R. Prieto, R. Yotti, P. Ávila, T. Álvarez, J.M. Gil-Jaurena, F. Fernández-Avilés.
Selection of the best in 2016 in congenital heart diseases.
Rev Esp Cardiol., 70 (2017), pp. 299-300
M. Mirowski, C.A. Shahkdneill, H.B. Taussig.
Long-Term (10 to 13 Years) Follow-up Study after Transventricular Pulmonary Valvulotomy for Pulmonary Stenosis with Intact Ventricular Septum.
Circulation., 28 (1963), pp. 906-914
M. Gurvitz, A.M. Valente, C. Broberg, et al.
Prevalence and predictors of gaps in care among adult congenital heart disease patients: HEART-ACHD (The Health. Education, and Access Research Trial).
J Am Coll Cardiol., 61 (2013), pp. 2180-2184
Copyright © 2019. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?